Pfizer's New Lung Cancer Treatment Fails to Meet Expectations in Trials
Pfizer's latest experimental drug, intended to replace conventional chemotherapy for lung cancer, has not achieved the desired results in clinical trials.
Pfizer has announced that its experimental lung cancer drug has not succeeded in clinical trials, falling short of expectations.
The drug was developed with the aim of providing an alternative to traditional chemotherapy for one of the most prevalent forms of lung cancer.
This outcome raises questions about the future direction of Pfizer's oncology research and the ongoing search for more effective cancer treatments.
Updates
Update at 21:36 UTC on 2026-06-22
STAT reported Pfizer said an experimental drug it hoped could replace a widely used chemotherapy in one of the most common forms of lung cancer fell short in a clinical trial.
Sources: STAT